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conservative surgery after partial breast irradiation (PBI) for primary 
tumor 
Materials and Methods: Patients with local recurrence in quadrants 
other than the previous one treated with full dose intraoperative 
electrons (ELIOT), who received a second breast conservative surgery, 
are enrolled in this ongoing phase I/II study called POLO ( Partially 
Omitted LObe). The primary endpoint is acute toxicity. The area 
previously irradiated with PBI is identified through surgical clips, 
inserted at the time of first quadrantectomy. The treatment volume 
comprise the whole breast minus the part previously irradiated with 
PBI. The whole breast and the recurrent tumor bed are planned to 
receive a dose of 45 Gy and 50 Gy , respectively, in 20 fractions, 
5d/wk within 4 weeks. According to the protocol, 5%, 25% 50% and 
95% of the area ELIOT should not receive more than 20Gy, 15 Gy, 10 
Gy and 5 Gy, respectively. Treatment plans are generated using 
helical tomotherapy (Tomotherapy Inc., Madison, WI) 
Results:  
  
So far, 3 patients entered the study. The mean age was 59 years. The 
histology at time of recurrence was invasive and the mean tumor size 
was 0.6 mm. All patients had quadrantectomy with negative margins 
and sentinel node biopsy. The mean time between initial radiotherapy 
and reirradiation was 100 months. All patients had been given PBI with 
21 Gy -full dose intraoperative electrons. The salvage radiotherapy 
comprises whole breast irradiation minus PBI area: by exploiting 
helical tomotherapy , a well-demarcated cold area of underdosage in 
the previously irradiated ELIOT area is created (Fig.1). The following 
treatment plan parameters are given as mean values. The 5%, 25%, 
50% and 95% of the volume of the previously ELIOT area were given 
21.6 Gy, 13.8 Gy, 8.8 Gy, 3.6 Gy respectively. Regarding the whole 
breast, V95% and V90% were 88.1% and 95.4%, respectively , Dmax was 
113.5 % ( with V 107% being 1,25 %) and Dmean were 99.5%. Proper 
DVH constraints and penalities are applied to improve target coverage 
while minimizing the previously irradiated area. Acute toxicity was 
excellent. During treatment the maximum RTOG grade was G2 
erithema (1 patient) and G2 patchy desquamation ( 1 patient) , not 
involving the ELIOT region. One month after, no side effects were 
recorded. 
Conclusions: Given the increased numbers of patients treated with 
conservative surgery and partial breast irradiation, the management 
of tumor reappearances in the untreated remaining breast is bound to 
be a matter of controversy. The technical feasibility of retreatment of 
the whole breast while sparing the primary tumor bed region 
previously irradiated with a PBI modality is a step to investigate.  
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Purpose/Objective: The advantage of Intensity Modulated 
Radiotherapy over tridimensional conformal radiotherapy (3D-CRT) for 
breast cancer remains controversial. However, target volume 
coverage and healthy tissue protection are not adequate with 3D-CRT 
under certain complex anatomical conditions. We present here the 
dosimetric results of the first patients treated with volumetric 
modulated arctherapy (VMAT) at our institution. 
Materials and Methods: Nine patients whose PTV coverage was 
unsatisfactory with 3D-CRT were selected. They were all replanned 
and treated with VMAT. A 7 mm extension was used to create the 
PTVs from the breast and lymph nodes CTVs, excluding the first 5 mm 
under the skin. Radiation was delivered by using two 6 MV photons 
partial arcs of 240°. The prescribed doses were 52.2 Gy to the breast 
and lymph nodes and 63.2 Gy to the tumor bed in 29 fractions, using 
the integrated boost method. Dosimetric results regarding PTV 
coverage and normal tissues protection (including contralateral 
breast, ipsilateral and contralateral lungs and heart) were collected. 
Results: On average, 90% and 95% of the breast PTV received 
respectively 97.2 % [93.2 -99, 9] and 91.7 % [80.6 - 98.2] of the 
prescribed dose. Ninety % and 95 % of the supraclavicular PTV 
received respectively 94.6 % [84 - 100] and 88.5 % [72-98] of the 
prescribed dose. For internal mammary chain volume, 90 % and 95 % 
of the PTV received respectively 96.4 % [87 - 100] and 90 % [75 - 100] 
of the prescribed dose. For ipsilateral lung, the volume receiving 5 Gy 
(V5) was 90 % [75-100], the volume receiving 20 Gy (V20) was 23.6% 
[13.7 - 35] and the volume receiving 30 Gy (V30) was 9.7% [4.7 - 14]. 
The average ipsilateral lung dose was 15 Gy [11-19]. For the 
contralateral lung, V5 was 38.9 % [16.6 to 68.5], V10 was 5.4 % [0-15] 
and the average dose was 5 Gy [3.4 to 7.2]. For the heart, V5 was 78.1 
% [49 - 100] and V35 was 0.8 % [0 -5]. The average heart dose was 14 
Gy [9-19]. For contralateral breast, V5 was 23.6 % [0.8 to 64.9] and 
V10 was 4.4 % [0 -20]. The average dose was 4.1 Gy [2.1 -7.3]. The 
average number of monitor unit was 568 [448-772]. 
Conclusions: RapidArc treatment yielded satisfactory PTV coverage 
while ensuring sufficient organs at risk protection for treatment plans 
that would not have been acceptable with 3D-CRT.  
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Purpose/Objective: Cancer epidemiology has been extensively 
studied in developed countries. However, data addressing the 
epidemiology and the impact of the implementation of screening 
programs for breast cancer in the Middle East are scarce. We present 
a detailed epidemiological analysis of breast cancer in the Jordan 
national cancer registry with special focus on presenting the impact of 
the implementation of a nationwide screening program for breast 
cancer in 2006 in an attempt to aid the continuously evolving 
strategies for improved cancer surveillance and control. 
Materials and Methods: Data from the Jordan national cancer registry 
addressing the periods from January 1996 to December 2008 were 
meticulously reviewed. The Jordan national cancer registry which was 
established in 1996 utilizes a passive and active capture system via 
liaison personnel throughout the country.Tumor stage was classified 
into local, regional, distant or unknown. Crude incidence rates are 
expressed per 100,000 population. 
Results: Between 1996 and 2008; a total of 7,794 breast cancer cases 
were registered. Overall, 7,018 patients (89.8%) harbored ductal 
carcinoma while 478 patients (6.1%) harbored lobular carcinoma. The 
crude incidence rate of breast cancer was 20 in 1996, 21.5 in 1997, 
20.2 in 1998, 22.9 in 1999, 23.7 in2000, 23.9 in 2001, 20.5 in 2002, 
22.1 in 2003, 24.9 in 2004, 25.5 in 2005,27.5 in 2006, 29.3 in 2007 and 
29.9 in 2008. Concerning the age distribution of breast cancer cases; 
28.8% occurred in 40-49, 26.4% in 50-59, 18% in 60-69,16.6% in 30-39 
and 6.8% in 70-79 age groups. The median age was 51 years(range, 16-
100 years). Overall for breast cancer; 1,412 patients (17.4%)harbored 
local disease, 1,504 patients (19.3%) harbored regional disease, 
and1,572 patients (18.3%) harbored metastatic disease while in 3,306 
patients (45.2%)staging data was missing. For patients with known 
cancer stage, 1,954 out of a total of 2,712 patients (72.1%) presenting 
prior to 2006 and 1,047 out of a total of 1,796 patients (58.3%) 
presenting after 2006 harbored loco-regional disease.  
Conclusions: This study represents the first comprehensive 
assessment of the epidemiology of breast cancer in Jordan basing a 
framework for enhancing strategic health plans regarding cancer 
surveillance and control in Jordan and the Middle East.  
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Purpose/Objective: With this study we intended to evaluate the dose 
received by axillary levels I and II, when irradiating the breast with 
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adjuvant intent. We compared plans with Foward Planning -IMRT (FP–
IMRT) adjusted to the delineated breast volume with two other plans 
without the breast delineated (one with standard tangential beams 
with wedges and another with FP-IMRT). The ACOSOG Z0011 trial 
showed the non inferiority of the irradiation of axillary levels I and II 
(included in the irradiated volume when using standard tangential 
beam radiotherapy to the breast) when compared with axillary 
dissection of the same levels, in selected patients with breast cancer.  
Materials and Methods: We analyzed data from 40 patients 
undergoing radiotherapy after breast conserving surgery, with a 
negative sentinel node biopsy. The patients were submitted to a CT 
for virtual simulation with 3mm slice. The data from the CT were 
doubled. In one CT, 2 dosimetry plans were done: one with 
conventional RT with tangential beams with wedges (2-3 segments 
were added if necessary to achieve dose homogeneity) and another 
with FP-IMRT. On the other CT data, target volumes were delineated: 
breast CTV and PTV (expansions of 10 mm were made for all 
directions except for the posterior one, which was 7 mm), and a plan 
was calculated using the FP-IMRT technique, adjusted to the PTV. We 
then outlined the axillary levels I and II, for analysis, on one CT data 
and copied it to the other. Mean dose (Dmean) and V95 were 
evaluated for axillary levels I and II. The Conformity Index (CI) of the 
PTV was also analysed. 
Results: Both V95 and Dmean for axillary level I were higher in the 
standard tangential beams with wedges technique and in the FP-IMRT 
technique without the breast volume delineated. When compared 
with these plans, the plan adjusted to the breast PTV achieved an 
inferior V95 value to axillary level I. When evaluating the axillary level 
II, these differences were more pronounced. We found a higher CI 
value in the plan adjusted to the breast target volume. 
Conclusions: We found a higher conformity index to the breast target 
volume using the FP-IMRT technique with the breast target volumes 
delineated, and a lower V95 for the axillary levels evaluated. This 
shows that when conforming the dose to the breast alone the 
unintended irradiation of the axilla is lower. Although a higher V95 
was achieved with the standard tangential breast irradiation with 
wedges, it happens at the expenses of a lower conformity index to the 
breast volume, and this technique has shown a higher rate of skin 
toxicity, which lead to being less used. We conclude that the 
delineation of axillary levels I and II is mandatory when there is the 
need to irradiate them, and the information obtained by the sentinel 
node biopsy is therefore important to the radiotherapy treatment. 
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Purpose/Objective: Treatment of locally-advanced rectal cancer with 
neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal 
excision has led to better results in sphincter-preservation and local 
recurrence rates in the last years. Achievement of a pathologic 
complete response (ypT0N0) after nCRT consistently associates to 
improved disease free and overall survival. However, no clinical or 
genetic predictorsof complete response are currently available which 
allow patient stratification and personalization of therapeutic 
strategies. Among the multiple pathways involved in CRT resistance, 
inflammatory response has been demonstrated to mediate both micro-
environmental resistance to radiation damage. To evaluate the role of 
functional polymorphisms of inflammatory response genes (NF-kB, 
Cox-1, Cox-2,IL-1beta) in pathological response to nCRT in rectal 
cancer. 
Materials and Methods: We included patients with locally advanced 
rectal cancer treated with nCRT (capecitabine, 3D pelvic 
radiotherapy, with TD 50.4 Gy) at asingle center. Genomic DNA was 
obtained from peripheral blood or paraffin-embedded non-tumor 
tissue. The following polymorphisms were analyzed with Taqman-
based qPCR: rs28362491(NF-Kβ), rs1213266 (COX-1), rs5789 (COX-1), 
rs20417 (COX-2), rs5275 (COX-2),rs16944 (IL-1β) and rs1143627 (IL-1β). 
Association between genotypes and rectal cancer outcome was 
analyzed with logistic regression models (SNPstatssoftware). 
Results: 159 patients have been included; Patient characteristics: 
median age 65 years, 104%males, 55% female. 95% of population had 
Karnofsky 90-100%; stages IIA (27%), IIIA(4%), IIIB (25%), IIIC (45%). 
Abdominoperineal resection was practiced in 30% and lower anterior 
resection in 70% of cases.Surgery included complete mesorectal 
excision in 78% of patient population.Adjuvant chemotherapy was 
administered in 88% of them. Complete pathological response (pCR) 
rate was 18% and nonresponse in 20%. With a median follow-up of 44 
months (range: 11-93), only 30 patients have recurred with local 
and/ormetastatic disease. Overall survival was 85,4% and desease free 
survival 81%.Univariate analysis shown statistically significant impact 
of NFkB associated to pCR and OS. Distribution of genotypic and allelic 
frequencies for the seven polymorphisms was similar to those 
observed in European populations.  
Conclusions: Our work is the first that analyze the relation between 
inflammation gene polymorphisms and response to nCRT in rectal 
cancer treatment. We did not find significant association between the 
genetic polymorphisms (s1213266, rs5789, rs20417, rs5275, rs16944, 
rs1143627) and the pathological response, but we observed impact of 
NF-Kb in relation between pathological response and overall survival. 
We also observed statistically significant relationship between 
performance status and treatment response. Patients with 100-90% 
Karnofsky have cPR or quasi complete pathological response to nCRT. 
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Purpose/Objective: To prospectively validate the efficacy of 18F-
fluorodeoxyglucose (18F-FDG)-positron emission tomo-graphy (PET)-CT 
imaging for predicting histopathological response and clinical long-
term outcomes in locally advanced rectal cancer (LARC). 
Materials and Methods: 38 patients with confirmed diagnosis of LARC 
(cT3–4 or cN+) were prospectively studied with 18F-FDG PET/CT 
before and after neoadjuvant therapy (NAT). Total mesorectal 
excision (TME) was programmed 6 weeks after NAT followed by an 
expert histopathological analysis of the surgical specimen. Baseline 
variables and previously identified cutoff values of pre-NAT 
(SUVmaxPRE ≥ 6), post-NAT (SUVmaxPOST < 2), absolute (?SUVmax ≥ 4) 
and percentage reduction (?SUVmax ≥ 65%) of the baseline maximum 
FDG standardized uptake value (SUVmax) criteria were applied to 
differentiate metabolic tumor responders from non-responders. These 
features were correlated with disease-free survival (DFS) and overall 
survival (OS).  
Results: 19 responder patients (TRG 3-4) showed a statistically 
significantly higher 5-year disease-free survival (DFS) and overall 
survival (OS) compared with 19 non-responders (TRG0-2) patients 
(94.4 vs 48.8%, p=0.001; 94.7 vs 63.2%, p= 0.02). At multivariate 
analysis the only presurgical parameters correlated to the likelihood 
of recurrence and survival were ?SUV (≥ 65% vs < 65%) [HR= 5.2 
(p=0.01); HR= 4.4 (p=0.03)] and tumor histologic grade (I or II vs III) 
[HR=6.2 (p=0.001); HR= 4.1 (p=0.03)].  
Conclusions: This prospective study has proven that 18F-FDG PET/CT 
is a valuable imaging tool for assessing rectal cancer TRG and long-
term prognosis, and could potentially serve as an intermediate 
endpoint in treatment optimization research and rectal cancer patient 
care. 
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Purpose/Objective: This prospective study evaluates feasibility, 
toxicity and early clinical outcomes of concurrent image guided 
volumetric modulated arc therapy (IG-RA) and weekly cisplatin in the 
setting of a definitive chemoradiotherapy for locally advanced 
esophageal cancer. 
Materials and Methods: 41 Patients diagnosed with squamous cell 
carcinoma of esophagus deemed unsuitable for surgery were included 
in the study. Patients with performance status (ECOG) more than 1, 
involvement of cervical esophagus or gastroesophageal junction, 
    
